ERBB2 and breast cancer: Unlike ER and HER-2 positive BC, TNBCs are highly resistant to current therapies as they are insensitive to endocrine and molecular-targeted therapies; currently, systemic chemotherapy and surgery are the backbone of TNBC management (6, 9).